We write on behalf of the UK National Screening Committee (UK NSC) in response to your article. 1 Any comparison of what screening decisions are made by different jurisdictions is very useful. It is particularly helpful to look at the decision-making processes as they are rarely documented in peerreviewed literature and your paper casts welcome light on these.
RCTs would be too large, expensive and long to provide useful information. The UK NSC uses the criteria to allow for an understanding of what would be ideal, but also recognises that in some circumstances that will not be available and so different evidence products are used. The UK NSC review and recommendation statements on the bloodspot conditions show the type of evidence that has informed the actual decision (https://legacyscreening.phe.org. uk/msud). It has recently been noted that decision-making relating to bloodspot screening has been lax. 2 So although it is recognised that RCTs may not be possible the UK NSC is also aware that the difficulty of generating evidence does not negate the difficulty of decisionmaking without it.
Second, somehow by recommending treatment guidelines the statement 'UK NSC seems to steer away from screening' is simply incorrect. A UK NSC criterion addresses the need for clinical management to be optimised prior to screening. This encourages reflection on the additional impact of screening over and above clinical care, for example, cascade testing in siblings or well-managed protocols for early presenting cases. Without these components the viability of screening programmes for rare diseases cannot be accurately evaluated. Neither can they operate effectively when implemented. The work we do on screening programmes is done hand in glove with clinicians caring for these very rare, very sick babies. We are committed not just to making good screening decisions but also to supporting our clinical partners and stakeholders in care for these babies. To achieve this it is essential that screening is not conceived as taking place in a vacuum. On behalf of the authors, I write to reply to the Letter to the Editor from Dr Mackie: UK National Screening Committee criteria: clarification of two misunderstandings, published in this issue of EJHG. We thank Dr Mackie and her team for taking the time to respond to our work and clarifying the review process from the UK perspective. As Dr Mackie's letter highlights, comparisons of screening decisions are useful, yet hard to construct, since decision processes are rarely documented in peer reviewed literature. 1,2 It is only through much needed international discourse around newborn screening that transparency and learnings across the globe can be achieved. In this instance, while efforts were made to engage programs across the globe to support such a discourse, more was needed in terms of reaching out specifically to the UK National Screening Committee (NSC). To this end, we very much welcome Dr Mackie's correspondence to ensure the UK's program is accurately represented.
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